Journal of the American Chemical Society
Article
selectivity factors.35 The presence of an aryl, alkenyl, alkynyl or
ester moiety adjacent to the NH group is apparently critical for
the enantioselectivity. Computational studies indicate that
cation-π interactions play a key role in the chiral recognition
of lactam substrates. There is no simple answer to the question
“which catalyst is the best?” Based on available data, Cl-PIQ has
broader substrate scope (see results with substrates 10, 22, 25,
and 37), while BTM exhibits higher enantioselectivity in the
KR of those substrates where a direct comparison has been
made (see Tables 1 and 2). As a rule, we have given priority to
BTM when exploring new substrates with proton affinities
equal to or lower than that of the conjugate base of 4-phenyl-
oxazolidin-2-one 5.
(4) E.g., chiral dirhodium carboxamidates: Doyle, M. P.; Duffy, R.;
Ratnikov, M.; Zhou, L. Chem. Rev. 2010, 110, 704.
(5) (a) Imidazolidin-4-ones as chiral enolate equivalents: Seebach,
D.; Sting, A, R.; Hoffmann, M. Angew. Chem., Int. Ed. Engl. 1996, 35,
2708 and references cited therein. (b) Vince lactam (2-
azabicyclo[2.2.1]hept-5-en-3-one) in the synthesis of pharmaceuticals:
Singh, R.; Vince, R. Chem. Rev. 2012, 112, 4642 and references cited
therein.
(6) Pyrrolidinones: (a) Proteasome inhibitor Lactacystin: Omura, S.;
Fujimoto, T.; Otoguro, K.; Matsuzaki, K.; Moriguchi, R.; Tanaka, H.;
Sasaki, Y. J. Antibiot. 1991, 44, 113. (b) Proteasome inhibitor
Salinosporamide A: Feling, R. H.; Buchanan, G. O.; Mincer, T. J.;
Kauffman, C. A.; Jensen, P. R.; Fenical, W. Angew. Chem., Int. Ed. 2003,
42, 355. (c) Angiogenesis inhibitor Streptopyrrolidine: Shin, H. J.;
Kim, T. S.; Lee, H.-S.; Park, J. Y.; Choi, I.-K.; Kwon, H. J.
Phytochemistry 2008, 69, 2363. (d) Cytokine modulator Cytoxazone
(oxazolidin-2-one): Kakeya, H.; Morishita, M.; Koshino, H.; Morita,
T.-i.; Kobayashi, K.; Osada, H. J. Org. Chem. 1999, 64, 1052. (e)
Tetramic acids (pyrrolidine-2,4-diones): Royles, B. J. L. Chem. Rev.
1995, 95, 1981. See also natural β-lactam antibiotics (ref 2d).
(7) Asymmetric synthesis of β-lactams: (a) C−H insertion: Doyle,
M. P.; Kalinin, A. V. Synlett 1995, 1075. (b) Staudinger reaction:
Hodous, B. L.; Fu, G. C. J. Am. Chem. Soc. 2002, 124, 1578. France, S.;
Weatherwax, A.; Taggi, A. E.; Lectka, T. Acc. Chem. Res. 2004, 37, 592.
Kinugasa reaction: Shintani, R.; Fu, G. C. Angew. Chem., Int. Edit.
2003, 42, 4082. (c) NHC-catalyzed annulation: He, M.; Bode, J. W. J.
Am. Chem. Soc. 2008, 130, 418.
(8) Dihydropyridones: (a) He, M.; Struble, J. R.; Bode, J. W. J. Am.
Chem. Soc. 2006, 128 (26), 8418. (b) Wanner, B.; Mahatthananchai, J.;
Bode, J. W. Org. Lett. 2011, 13, 5378. (c) Simal, C.; Lebl, T.; Slawin, A.
M. Z.; Smith, A. D. Angew. Chem., Int. Edit. 2012, 51, 3653.
(9) See, e.g., (a) rac-Imidazolidin-4-ones: Zehavi, U.; Ben-lshai, D. J.
Org. Chem. 1961, 26, 1097. See also ref 5a. rac-β-Lactams:
(b) Rasmussen, J. K.; Hassner, A. Chem. Rev. 1976, 76, 389. rac-
Oxazolidinones: (c) Ishibuchi, S.; Ikematsu, Y.; Ishizuka, T.; Kunieda,
T. Tetrahedron Lett. 1991, 32, 3523. (d) Espino, C. G.; Du Bois, J.
Angew. Chem., Int. Ed. 2001, 40, 598. (e) He, M.; Bode, J. W. Org. Lett.
2005, 7, 3131. See also ref 5b.
ASSOCIATED CONTENT
■
S
* Supporting Information
General experimental details, previously unreported kinetic
resolution data, characterization and preparation data for
previously unreported compounds, details of computational
studies. This material is available free of charge via the Internet
AUTHOR INFORMATION
■
Corresponding Author
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank Dr. Yuhua Zhang for providing preliminary data with
catalyst 4b. Financial support for these studies has been
provided by National Institutes of Health (R01 GM072682 to
V.B.B.) and National Science Foundation (CHE-1059084 to
K.N.H.; CHE-1012979 to V.B.B.). Calculations were per-
formed on the Hoffman2 cluster at UCLA and the Extreme
Science and Engineering Discovery Environment (XSEDE),
which is supported by the National Science Foundation (OCI-
1053575).
(10) For a review of resolution methods, see: Faigl, F.; Fogassy, E.;
Nog
519.
́
rad
́
i, M.; Pal
́
ovics, E.; Schindler, J. Tetrahedron Asymm. 2008, 19,
(11) Catalyst development and enantioselective O-acylation: (a) Bir-
man, V. B.; Uffman, E. W.; Jiang, H.; Li, X.; Kilbane, C. J. J. Am. Chem.
Soc. 2004, 126, 12226. (b) Birman, V. B.; Jiang, H. Org. Lett. 2005, 7,
3445. (c) Birman, V. B.; Li, X. Org. Lett. 2006, 8, 1351. (d) Birman, V.
B.; Li, X. Org. Lett. 2008, 10, 1115. (e) Li, X.; Liu, P.; Houk, K. N.;
Birman, V. B. J. Am. Chem. Soc. 2008, 130, 13836. (f) Li, X.; Jiang, H.;
Uffman, E. W.; Guo, L.; Zhang, Y.; Yang, X.; Birman, V. B. J. Org.
Chem. 2012, 77, 1722 and references cited therein.
(12) Enantioselective N-acylation: (a) Birman, V. B.; Jiang, H.; Li, X.;
Guo, L.; Uffman, E. W. J. Am. Chem. Soc. 2006, 128, 6536. (b) Yang,
X.; Bumbu, V. D.; Birman, V. B. Org. Lett. 2011, 13, 4755.
(13) Enantioselective alcoholysis of acyl donors: (a) Yang, X.; Lu, G.;
Birman, V. B. Org. Lett. 2010, 12, 892. (b) Yang, X.; Birman, V. B.
Angew. Chem., Int. Ed. 2011, 50, 553. (c) Yang, X.; Birman, V. B.
Chem.Eur. J. 2011, 17, 11296. (d) Bumbu, V. D.; Birman, V. B. J.
Am. Chem. Soc. 2011, 133, 13902. (e) Liu, P.; Yang, X.; Birman, V. B.;
Houk, K. N. Org. Lett. 2012, 14, 3288. (f) Yang, X.; Liu, P.; Houk, K.
N.; Birman, V. B. Angew. Chem., Int. Ed. 2012, 51, 9776.
REFERENCES
■
(1) We define the terms “lactams” and “thiolactams” broadly, to
describe any structure containing an amide −CO−NR− or thioamide
−CS−NR− moiety within a ring that may or may not contain
additional heteroatoms.
(2) (a) Phosphodiesterase inhibitor Rolipram (pyrrolidinone):
Schwabe, U.; Miyake, M.; Ohga, Y.; Daly, J. W. Mol. Pharmacol. 1976,
12, 900. (b) Antibiotic Linezolid (oxazolidin-2-one): Brickner, S. J.;
Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D.
A.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C.
W.; Zurenko, G. E. J. Med. Chem. 1996, 39, 673. (c) Cholesterol-
lowering drug Ezetimibe (β-lactam): Rosenblum, S. B.; Huynh, T.;
Afonso, A.; Davis, H. R.; Yumibe, N.; Clader, J. W.; Burnett, D. A. J.
Med. Chem. 1998, 41, 973. (d) Testero, S. A.; Fisher, J. F.; Mobashery,
S. β-Lactam antibiotics. In Burger’s Medicinal Chemistry, Drug Discovery
and Development, 7th ed.; Abraham, D. J., Rotella, D. P., Eds.; Wiley:
Hoboken, NJ, 2010; Vol. 7 (Antiinfectives), pp 259−404.
(14) Kagan, H. B.; Fiaud, J. C. Top. Stereochem. 1988, 18, 249.
(15) For a recent review, see: Krasnov, V. P.; Gruzdev, D. A.; Levit,
G. L. Eur. J. Org. Chem. 2012, 1471.
(16) For a review of enzymatic KR of amines: van Rantwijk, F.;
Sheldon, R. A. Tetrahedron 2004, 60, 501.
(3) Oxazolidin-2-ones: (a) Evans, D. A. Aldrichimica Acta 1982, 15,
23. (b) Ager, D. J.; Prakash, I.; Schaad, D. R. Aldrichimica Acta 1997,
(17) For recent reviews of nonenzymatic kinetic resolution and
́
30, 3. Oxazolidine-2-thiones and thiazolidine-2-thiones: (c) Velazquez,
enantioselective acylation catalysts, see: (a) Muller, C. E.; Schreiner, P.
F.; Olivo, H. F. Curr. Org. Chem. 2002, 6, 1. (d) Delaunay, D.; Toupet,
L.; Corre, M. L. J. Org. Chem. 1995, 60, 6604. Camphor-derived
lactams: (e) Boeckman, R. K.; Boehmler, D. J.; Musselman, R. A. Org.
Lett. 2001, 3, 3777.
̈
R. Angew. Chem., Int. Ed. 2011, 50, 6012. (b) Pellissier, H. Adv. Synth.
Catal. 2011, 353, 1613. (c) Spivey, A. C.; Arseniyadis, S. Top. Curr.
Chem. 2010, 291, 233. (d) Denmark, S. E.; Beutner, G. L. Angew.
17611
dx.doi.org/10.1021/ja306766n | J. Am. Chem. Soc. 2012, 134, 17605−17612